Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
ROIV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.73 - $13.06
Previous CloseN/A
Volume1.46M
Average Volume (3M)5.64M
Market Cap
$7.91B
Enterprise Value$2.85B
Total Cash (Recent Filing)$4.89B
Total Debt (Recent Filing)$100.17M
Price to Earnings (P/E)1.9
Beta0.96
Next Earnings
Aug 11, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding679,806,100
10 Day Avg. Volume3,883,123
30 Day Avg. Volume5,636,256
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue37.37
Enterprise Value/Gross Profit40.59
Enterprise Value/Ebitda-4.13
Forecast
1Y Price Target
$16.00Price Target Upside38.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Earnings PotentialBrepocitinib is highly differentiated in its convenient oral dosing and novel mechanism-of-action, with potential to become the first approved JAK inhibitor in the dermatomyositis space.
Stock BuybackROIV disclosed that it had repurchased $205M in stock and announced a new authorization for the repurchase of up to $500M in stock.
Trial ManagementManagement emphasized careful trial management, including actions to reduce placebo variability, which boosts confidence in the trial's success.
Bears Say
Placebo ConcernsInvestors may be overly concerned about the placebo response in the forthcoming Ph3 brepocitinib dermatomyositis trial results, and there are signals that JAK inhibitors benefit muscle.
Trial RisksThe trial carries some risks due to the lack of randomized experience with brepocitinib in the indication.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $8.73 and its highest was $13.05 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $7.91B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Aug 11, 2025 which is in 3 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on May 29, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.264 by -$0.026.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.25.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 679,806,100 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.264. Following the earnings report the stock price went up 6.403%.
Which hedge fund is a major shareholder of Roivant Sciences?
Currently, no hedge funds are holding shares in ROIV
Roivant Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (38.53% Upside)
$16.00 (38.53% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $45.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.77%
12-Months-Change
Fundamentals
Return on Equity
-8.56%
Trailing 12-Months
Asset Growth
-24.72%
Trailing 12-Months
Company Description
Roivant Sciences
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Roivant's earnings call presented a strong financial position and promising developments in its pipeline, particularly with Brepocitinib and IMVT-1402. However, challenges remain in terms of competition in the FcRn space and ongoing litigation. The sentiment is balanced with significant growth potential but also notable risks.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$16.00
▲(38.53% Upside)
Technical Analysis
Halozyme
―
Jazz Pharmaceuticals
―
Madrigal Pharmaceuticals
―
BridgeBio Pharma
―
Legend Biotech
―
Ownership Overview
27.97% Insiders
13.41% Mutual Funds
0.28% Other Institutional Investors
45.03% Public Companies and
Individual Investors